Celgene Corp., a $12.5b developer of therapies for cancer and inflammatory diseases is buying Juno Therapeutics Inc., a Seattle-based biotech company making cutting-edge cancer immunotherapy treatments. The Deal expands Celgene’s portfolio of blood-cancer drugs. Juno is one of leaders in a new kind of cancer treatment, known as CAR-T, that takes a patient’s own immune cells, modifies them and then sets them loose to hunt down and attack tumors. Deal Value - $9b, on sales of $13b(0.69x), and $4.3b in EBITDA(2.09x).
Keywords: Healthcare Investment Banking, Healthcare M&A, Healthcare mergers